排序方式: 共有33条查询结果,搜索用时 686 毫秒
1.
2.
目的探讨哮喘儿童吸入糖皮质激素(ICS)治疗前后血清总IgE的变化及意义。方法选择2005年12月-2007年11月本院儿童哮喘门诊哮喘患儿351例。诊断标准参照全国儿童哮喘协作组标准。随机分为对照组(118例),ICS组(233例)。对照组主要以非特异性免疫调节剂治疗为主。ICS组〈5岁(162例)患儿选用储雾罐吸入氟替卡松气雾剂(辅舒酮),≥5岁(71例)患儿选用沙美特罗替卡松粉吸入剂(舒利迭)。对照组与ICS组分别于治疗前和治疗3个月运用全自动过敏原定量分析仪测定其血清IgE,ICS组继续治疗至1a,复查测定其血清IgE水平。结果对照组治疗前及治疗3个月IgE水平分别为(360.14±34.43)ng/L、(385.07±32.36)ng/L(P〉0.05);ICS组治疗前、治疗3个月及1aIgE分别为(586.26±42.39)ng/L、(453.12±30.74)ng/L、(421.96±25.73)ng/L,治疗前与治疗3个月比较有显著差异(t=4.744P〈0.01),治疗3个月与治疗1a比较无明显差异(t=1.384P〉0.05)。ICS治疗3个月,辅舒酮治疗者(162例)中107例(66.05%)控制,舒利迭治疗者(71例)中52例(73.24%)控制,二组比较无明显差异(P〉0.05)。辅舒酮治疗者中126例(77.78%)IgE水平下降,舒利迭治疗者中43例(60.56%)IgE下降,二组比较差异有显著性意义(P〈0.01)。结论ICS氟替卡松治疗儿童哮喘中等剂量可使血清IgE下降,IgE的检测有利于哮喘患儿诊治过程中的体内变态反应状况的观察。IgE下降在哮喘急性期明显,缓解期下降缓慢。二种不同剂型的ICS均能有好的临床疗效,但在降低血清IgE水平方面,舒利迭则不及辅舒酮。 相似文献
3.
4.
酚妥拉明用于佐治心衰,重症肺炎,毛细支气管炎等有一定疗效。但在临床使用过程中,其副作用较多。1996年5月至1996年8月作者等对住院患儿使用本药的副作用进行了临床观察。现报道如下。1临床资料1.1一般资料本组42例,其中男29例,女13例,年龄2个... 相似文献
5.
Objective To discuss the significance of serum IgE before and after inhale glucocorticoid treat-ment of children's asthma. Methods 520 children with asthma were seleceted from the outpatient. Different type of fluticasone propionate were given to different age groups: Aerosol type by a spacer in less than 5 years old,and in-halant (Seretide) 5 years and the above. The dosage was between 200 μg/day to 375 μg/day. IgE was tested before and 3 months after the treatment. Results Serum IgE decreased significantly in 3 months treatment [ from (496.12±24.75) kU/L to (390.71±18.71) kU/L] (t=7.337,P<0.01). The change of IgE was related to clinical effect and age. The level increased in those less than 3 years [(307.05±34.71)kU/L vs (483.09±41.78) kU/L] (t=2.963,P=0.004),but decreased between 4 to 5 years old group [(543.46±51.03) kU/L vs (316.93±29.30) kU/L] (t=3.368,P=0.000) ,and decreased between 6 to 14 years old group[ (586.30±37.19)kU/L vs (387.61±27.60) kU/L] (t=4.827,P=0.000). In fluticasone group IgE level changed from (468.91±32.81) kU/L to (359.03±22.79) kU/L after treatment (t=5.988,P<0.01),which decreased from (586.30±37.19) kU/L to (387.6±27.60) kU/L in Salmeterol group (t=4.827,P<0.01). In 260 cases of IgE below 300 kU/L 109 cases (41.92%,109/260) increased while in 260 cases of IgE above 300 kU/L,total IgE lev-el increased in 45 cases (16.15% ,45/260) after treatment,with statistical significance(χ<'2>=37.789,P=0.000). Conclusion Inhale glucocorticoid can make the level of IgE decreased. 相似文献
6.
目的了解长沙地区急性下呼吸道感染(ALRTI)儿童呼吸道合胞病毒(RSV)及人偏肺病毒(hMPV)的流行病学特点和临床特征。方法收集2007年9月-2008年8月湖南省人民医院儿科医学中心1 165例ALRTI住院儿童鼻咽抽吸物样本,进行RSV及hMPV基因检测。对RSV和hMPV感染患儿流行病学特点、临床表现及实验室检查结果等进行比较。结果 1 165例样本检出RSV阳性标本315例,检出率为27.04%,1岁以下患儿占64.1%;hMPV阳性76例,检出率为6.52%,1岁以下患儿占63.15%;RSV感染全年均有发生,第一年11月到次年2月份为检出高峰,hMPV的检出高峰在3-4月;RSV感染病例气促的发生率高于hMPV感染病例(P〈0.05),发热、喘息、呕吐、腹泻的发生率两种病毒间差异无统计学意义(P〉0.05);RSV、hMPV感染病例白细胞、C-反应蛋白、转氨酶及心肌酶等实验室指标变化比较差异无统计学意义(P〉0.05);影像学检查同以散在肺部实变或间质病变为主,鲜有累及大片肺叶及胸膜。14例患儿同时存在RSV及hMPV感染,混合感染率1.20%(14/1 165)。RSV及hMPV协同感染患儿发绀几率较单一RSV感染患儿高(P〈0.05),白细胞升高几率大于单一感染者(P〈0.05),而喘息、气促、呕吐、腹泻发生率及C-反应蛋白、转氨酶、心肌酶等实验室检测指标变化与单一RSV或hMPV感染比较差异无统计学意义(P〉0.05);单一hMPV感染患儿的发热率高于单一RSV感染或两者协同感染患儿(P〈0.05)。单一感染和协同感染病例间病程、住院天数及预后比较差异无统计学意义(P〉0.05)。结论 RSV及hMPV均是引起长沙地区婴幼儿下呼吸道感染的重要病原,流行季节相近,具有相似的临床特征及影像改变,临床上难以鉴别。RSV感染较hMPV感染患儿更易发生气促,而hMPV感染则相对更易出现发热症状。混合hMPV感染可能有加重RSV感染患儿呼吸道症状的趋势。 相似文献
7.
8.
目的 探讨儿童塑型性支气管炎的临床特点及病原学分析。方法 回顾分析2011~2012 年9 例确诊为塑型性支气管炎患儿的临床资料,对其临床、影像、纤维支气管镜(纤支镜)特点、病原体及治疗进行总结。结果 9 例患儿均以高热、咳嗽起病,在发病1~3 d 出现呼吸困难,并进行性加重;一侧或双侧肺部呼吸音减低,肝脾肿大;合并呼吸衰竭6 例次、中毒性脑病6 例次、中毒性肝炎7 例次、休克3 例次、心力衰竭3 例次、肾功能衰竭2 例次。胸片或胸部CT 均表现为单个及多个肺叶段实变及不张, 4 例合并胸腔积液。纤支镜镜下均可见灰白色黏液栓堵塞支气管开口,吸出支气管样塑形物。9 例患儿均检出流感病毒(IFVs),以甲型流感病毒(IFV-A)为主(67%)。IFV-A 合并肺炎支原体及细菌的混合感染率为50%。3 例乙型流感病毒(IFV-B)感染患儿中,1 例合并肺炎支原体感染。9 例患儿均予抗感染、激素、丙种球蛋白及必要的呼吸支持治疗;均经纤支镜行内生异物取出及肺泡灌洗治疗;5 例予奥司他韦抗病毒治疗。痊愈7 例,死亡2 例。结论 儿童塑型性支气管炎临床与重症肺炎类似;流感病毒是其主要病原;治疗上除抗感染、糖皮质激素、丙种球蛋白、呼吸支持等常规治疗外,经纤支镜内生异物取出及早期奥司他韦抗病毒治疗可获得良好疗效。 相似文献
9.
Objective To discuss the significance of serum IgE before and after inhale glucocorticoid treat-ment of children's asthma. Methods 520 children with asthma were seleceted from the outpatient. Different type of fluticasone propionate were given to different age groups: Aerosol type by a spacer in less than 5 years old,and in-halant (Seretide) 5 years and the above. The dosage was between 200 μg/day to 375 μg/day. IgE was tested before and 3 months after the treatment. Results Serum IgE decreased significantly in 3 months treatment [ from (496.12±24.75) kU/L to (390.71±18.71) kU/L] (t=7.337,P<0.01). The change of IgE was related to clinical effect and age. The level increased in those less than 3 years [(307.05±34.71)kU/L vs (483.09±41.78) kU/L] (t=2.963,P=0.004),but decreased between 4 to 5 years old group [(543.46±51.03) kU/L vs (316.93±29.30) kU/L] (t=3.368,P=0.000) ,and decreased between 6 to 14 years old group[ (586.30±37.19)kU/L vs (387.61±27.60) kU/L] (t=4.827,P=0.000). In fluticasone group IgE level changed from (468.91±32.81) kU/L to (359.03±22.79) kU/L after treatment (t=5.988,P<0.01),which decreased from (586.30±37.19) kU/L to (387.6±27.60) kU/L in Salmeterol group (t=4.827,P<0.01). In 260 cases of IgE below 300 kU/L 109 cases (41.92%,109/260) increased while in 260 cases of IgE above 300 kU/L,total IgE lev-el increased in 45 cases (16.15% ,45/260) after treatment,with statistical significance(χ<'2>=37.789,P=0.000). Conclusion Inhale glucocorticoid can make the level of IgE decreased. 相似文献
10.
吸入糖皮质激素对哮喘儿童血清IgE的影响 总被引:1,自引:1,他引:0
目的 探讨哮喘儿童吸入糖皮质激素(ICS)治疗前后血清总IgE的变化及意义.方法 哮喘儿童520例,均给予ICS治疗.≤3岁142例,4~5岁169例,均给予储雾罐吸入丙酸氟替卡松气雾剂治疗;6~14岁209例,选用沙美特罗替卡松粉吸入剂治疗;剂量为200~375μg/d.治疗前与治疗后3个月复查IgE.结果 520例患儿治疗前IgE为(496.12±24.75)kU/L,治疗后IgE为(390.71±18.71)kU/L,差异有统计学意义(t=7.337,P<0.01).≤3岁组治疗前IgE为(307.05±34.71)kU/L,治疗后IgE为(483.09±41.78)kU/L,差异有统计学意义(t=2.963,P=0.004);4~5岁组治疗前ISE为(543.46±51.03)kU/L,治疗后IgE为(316.93±29.30)kU/L,差异有统计学意义(t=3.368,P=0.000);6~14岁组治疗前IgE为(586.30±37.19)kU/L,治疗后IgE为(387.61±27.60)kU/L,差异有统计学意义(t=4.827,P=0.000).氟替卡松治疗组治疗前IgE为(468.91±32.81)kU/L,治疗后IgE为(359.03±22.79)kU/L,差异有统计学意义(t=5.988,P<0.01);沙美特罗替卡松治疗组治疗前IgE为(586.30±37.19)kU/L,治疗后IgE为(387.61±27.60)kU/L,差异有统计学意义(t=4.827,P<0.01).治疗前IgE≤300 kU/L 260例,109例(41.92%,109/260)治疗后IgE升高;>300 kU/L 260例,45例(16.15%,45/260)治疗后血清总IgE升高,差异有统计学意义(χ<'2>=37.789,P=0.000).结论 ICS使IgE下降,IgE的检测有利于哮喘患者诊治过程中的病情观察. 相似文献